Radiotherapy is one of the treatment options for locally or regionally advanced prostate cancer, but radioresistance of prostate
cancer cells is a practical limitation of radiotherapy. The identification of molecular targets of radioresistance in prostate cancer is important
to improve therapeutic intervention. The aim of this review is to give more biological insight into some well known processes involved
in radioresistance of prostate cancer especially Apoptotic pathway; DNA damage response; and NF-κB(nuclear factor kappalight-
chain-enhancer of activated B cells) signaling pathway. This review integrates salient, published, research findings with underlying
molecular mechanisms, preclinical efficacy, and potential clinical applications of combining radiotherapy with these molecular targeted
agents for the treatment of prostate cancer.